The ISCIII allocates 30 million with FORTALECE to promote the health R&D&I work of the Health Research Institutes
28 December, 2023
Intermittent fasting: is the scientific evidence for or against it?
2 January 2024
Cope and Onda Cero have echoed the launch of the second research project in Spain on male breast cancer with the help of IIS Aragón and the INVI Association
Breast cancer is the most common cancer among women and self-examination, screening programs and different advances in research mean that survival from this type of cancer has considerably increased. But breast cancer not only affects women, men also suffer from it and Aragón is at the forefront of its research.
Around 700 men are diagnosed with breast cancer a year In Spain, it affects about 11.000 men and represents a 1,5% of cases of this type of cancer. Ignorance leads to 80% of diagnoses are in advanced stages. The good news is that we want to give a boost to research to reverse these figures and it is done through the “Antonio” project. TOlberto Jiménez Schumacher, ARAID researcher and head of the Molecular Oncology Group at the Aragón Health Research Institute, explains that the name has been given in tribute to the father of a friend of his who suffered breast cancer.
And there are men, like Màrius Soler, founder and president of the INVI Male Breast Cancer Association, who suffer from this cancer, but since it is silenced, when it is diagnosed it is already in advanced stages. In the case of Màrius, he was already detected in stage IV and was given one year to live. Prognosis that has been lengthened thanks to research.
Thanks to the agreement signed by the Health Research Institute of and the Male Breast Cancer Association, our community is at the forefront of research into this type of cancer, with the objective of accelerating the preclinical phases and finding similarities and differences with female breast cancer to increase the quality of life and survival of all patients.
Jiménez Schumacher assures that at this moment there are more questions than answers, but through cellular models in mice xenografted with tumors and metastatic lines with tropism in certain organs, it will allow therapies to be tested in preclinical phases. Starting by evaluating the studies that are already underway in the group and that are being analyzed in breast cancer in samples derived from women.
